Establishing an immune correlate of protection for Nipah virus in nonhuman primates
Abstract The limited but recurrent outbreaks of the zoonotic Nipah virus (NiV) infection in humans, its high fatality rate, and the potential virus transmission from human to human make NiV a concerning threat with pandemic potential. There are no licensed vaccines to prevent infection and disease....
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2024-12-01
|
| Series: | npj Vaccines |
| Online Access: | https://doi.org/10.1038/s41541-024-01036-2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850244191917965312 |
|---|---|
| author | V. H. Leyva-Grado D. Promeneur K. N. Agans G. G. Lazaro V. Borisevich D. J. Deer A. Luckay M. Egan A. S. Dimitrov B. Small C. C. Broder R. W. Cross S. Hamm T. W. Geisbert |
| author_facet | V. H. Leyva-Grado D. Promeneur K. N. Agans G. G. Lazaro V. Borisevich D. J. Deer A. Luckay M. Egan A. S. Dimitrov B. Small C. C. Broder R. W. Cross S. Hamm T. W. Geisbert |
| author_sort | V. H. Leyva-Grado |
| collection | DOAJ |
| description | Abstract The limited but recurrent outbreaks of the zoonotic Nipah virus (NiV) infection in humans, its high fatality rate, and the potential virus transmission from human to human make NiV a concerning threat with pandemic potential. There are no licensed vaccines to prevent infection and disease. A recombinant Hendra virus soluble G glycoprotein vaccine (HeV-sG-V) candidate was recently tested in a Phase I clinical trial. Because NiV outbreaks are sporadic, and with a few cases, licensing will likely require an alternate regulatory licensing pathway. Therefore, determining a reliable vaccine correlate of protection (CoP) will be critical. We assessed the immune responses elicited by HeV-sG-V in African Green monkeys and its relationship with protection from a NiV challenge. Data revealed values of specific binding and neutralizing antibody titers that predicted survival and allowed us to establish a mechanistic CoP for NiV Bangladesh and Malaysia strains. |
| format | Article |
| id | doaj-art-08b0bdd2ed914374abfdd11b8ee3a97e |
| institution | OA Journals |
| issn | 2059-0105 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | npj Vaccines |
| spelling | doaj-art-08b0bdd2ed914374abfdd11b8ee3a97e2025-08-20T01:59:48ZengNature Portfolionpj Vaccines2059-01052024-12-019111110.1038/s41541-024-01036-2Establishing an immune correlate of protection for Nipah virus in nonhuman primatesV. H. Leyva-Grado0D. Promeneur1K. N. Agans2G. G. Lazaro3V. Borisevich4D. J. Deer5A. Luckay6M. Egan7A. S. Dimitrov8B. Small9C. C. Broder10R. W. Cross11S. Hamm12T. W. Geisbert13Auro Vaccines LLCAuro Vaccines LLCGalveston National Laboratory, University of Texas Medical BranchAuro Vaccines LLCGalveston National Laboratory, University of Texas Medical BranchGalveston National Laboratory, University of Texas Medical BranchAuro Vaccines LLCAuro Vaccines LLCDepartment of Microbiology and Immunology, Uniformed Services UniversityCoalition for Epidemic Preparedness Innovations (CEPI)Department of Microbiology and Immunology, Uniformed Services UniversityGalveston National Laboratory, University of Texas Medical BranchAuro Vaccines LLCGalveston National Laboratory, University of Texas Medical BranchAbstract The limited but recurrent outbreaks of the zoonotic Nipah virus (NiV) infection in humans, its high fatality rate, and the potential virus transmission from human to human make NiV a concerning threat with pandemic potential. There are no licensed vaccines to prevent infection and disease. A recombinant Hendra virus soluble G glycoprotein vaccine (HeV-sG-V) candidate was recently tested in a Phase I clinical trial. Because NiV outbreaks are sporadic, and with a few cases, licensing will likely require an alternate regulatory licensing pathway. Therefore, determining a reliable vaccine correlate of protection (CoP) will be critical. We assessed the immune responses elicited by HeV-sG-V in African Green monkeys and its relationship with protection from a NiV challenge. Data revealed values of specific binding and neutralizing antibody titers that predicted survival and allowed us to establish a mechanistic CoP for NiV Bangladesh and Malaysia strains.https://doi.org/10.1038/s41541-024-01036-2 |
| spellingShingle | V. H. Leyva-Grado D. Promeneur K. N. Agans G. G. Lazaro V. Borisevich D. J. Deer A. Luckay M. Egan A. S. Dimitrov B. Small C. C. Broder R. W. Cross S. Hamm T. W. Geisbert Establishing an immune correlate of protection for Nipah virus in nonhuman primates npj Vaccines |
| title | Establishing an immune correlate of protection for Nipah virus in nonhuman primates |
| title_full | Establishing an immune correlate of protection for Nipah virus in nonhuman primates |
| title_fullStr | Establishing an immune correlate of protection for Nipah virus in nonhuman primates |
| title_full_unstemmed | Establishing an immune correlate of protection for Nipah virus in nonhuman primates |
| title_short | Establishing an immune correlate of protection for Nipah virus in nonhuman primates |
| title_sort | establishing an immune correlate of protection for nipah virus in nonhuman primates |
| url | https://doi.org/10.1038/s41541-024-01036-2 |
| work_keys_str_mv | AT vhleyvagrado establishinganimmunecorrelateofprotectionfornipahvirusinnonhumanprimates AT dpromeneur establishinganimmunecorrelateofprotectionfornipahvirusinnonhumanprimates AT knagans establishinganimmunecorrelateofprotectionfornipahvirusinnonhumanprimates AT gglazaro establishinganimmunecorrelateofprotectionfornipahvirusinnonhumanprimates AT vborisevich establishinganimmunecorrelateofprotectionfornipahvirusinnonhumanprimates AT djdeer establishinganimmunecorrelateofprotectionfornipahvirusinnonhumanprimates AT aluckay establishinganimmunecorrelateofprotectionfornipahvirusinnonhumanprimates AT megan establishinganimmunecorrelateofprotectionfornipahvirusinnonhumanprimates AT asdimitrov establishinganimmunecorrelateofprotectionfornipahvirusinnonhumanprimates AT bsmall establishinganimmunecorrelateofprotectionfornipahvirusinnonhumanprimates AT ccbroder establishinganimmunecorrelateofprotectionfornipahvirusinnonhumanprimates AT rwcross establishinganimmunecorrelateofprotectionfornipahvirusinnonhumanprimates AT shamm establishinganimmunecorrelateofprotectionfornipahvirusinnonhumanprimates AT twgeisbert establishinganimmunecorrelateofprotectionfornipahvirusinnonhumanprimates |